证券代码：002082 证券简称：万邦德 公告编号：2025-038 万邦德医药控股集团股份有限公司 关于子公司石杉碱甲控释片获得伦理批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦 德制药集团有限公司的 2.2 类新药石杉碱甲控释片治疗轻中度阿尔茨海默病型 痴呆的关键注册临床试验近日获得了组长单位首都医科大学宣武医院伦理审查 委员会的审查批件，批准项目开展。现将相关情况公告如下： 一、药品及获得伦理批件基本情况 名称：石杉碱甲控释片 英文名称：Huperzine A Controlled-Release Tablets 剂型：片剂 规格：0.2mg 注册分类：2.2 类新药 适应症：轻中度阿尔茨海默病型痴呆 临床研究阶段：Ⅱ/Ⅲ期 临床研究组长单位：首都医科大学宣武医院 伦理审查委员会审查意见：同意临床试验 二、药品临床试验进展情况 石杉碱甲控释片是公司自主研发的用于治疗轻中度阿尔茨海默病型痴呆的 2.2 类新药，采用双相控释技术，平缓药物释放峰谷曲线，并延长药物体内释放 时间，实现 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

证券代码：002082 证券简称：万邦德 公告编号：2025-037 万邦德医药控股集团股份有限公司 关于子公司取得发明专利的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）子公司万邦德制药 集团有限公司近日收到国家知识产权局的《发明专利证书》，具体情况如下： | 发明名称 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其 制备方法和应用 | | --- | --- | | 专利类型 | 发明专利 | | 专利号 | 202510032192.2 | | 授权公告日 | 2025.6.10 | | 专利权人 | 万邦德制药集团有限公司 | 本专利创造性的通过氘代修饰技术对石杉碱甲进行结构优化，成功研发出氘 代石杉碱甲新型化合物。石杉碱甲是一种天然生物碱，长期作为胆碱酯酶抑制剂， 用于改善阿尔茨海默病等神经退行疾病患者的认知功能。本次改良，通过将药物 分子中的特定氢原子替换为氘同位素，该化合物较原结构化学稳定性更高、毒性 更小、且延长了代谢半衰期，有望在维持疗效的同时降低给药频率和副作用。 上述专利不会对 ...

Group 1 - The innovation drug sector is experiencing a strong performance due to the recent issuance of a policy aimed at improving public health insurance and supporting innovative drugs [1] - The policy includes the establishment of a commercial health insurance directory for innovative drugs, which is expected to accelerate the development of innovative pharmaceuticals [1] - Several listed pharmaceutical companies have responded to the surge in stock prices, indicating significant market interest and volatility [1] Group 2 - Changshan Pharmaceutical announced a stock price increase of 147.69% from May 6 to June 9, with a cumulative deviation of over 30% in the last two trading days [2] - The company’s Abenanide injection has not yet been launched, and there is uncertainty regarding its approval and market competition [2] - Guoyuan Securities expressed optimism about the future of the innovative drug sector in China, highlighting ongoing research and development progress as a catalyst for investment opportunities [2]

证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.32亿元，其中，买入成交额为7642.47 万元，卖出成交额为5565.78万元，合计净买入2076.70万元。 万邦德今日上涨6.87%，全天换手率19.86%，成交额9.41亿元，振幅15.30%。龙虎榜数据显示，机构净 买入954.35万元，营业部席位合计净买入1122.35万元。 深交所公开信息显示，当日该股因日振幅值达15.30%上榜，机构专用席位净买入954.35万元。 具体来看，今日上榜的营业部中，共有1家机构专用席位现身，即买三，买入金额1329.87万元，卖出金 额375.51万元，合计净买入954.35万元。 万邦德6月9日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 联储证券股份有限公司浙江分公司 | 1707.51 | 9.65 | | 买二 | 天风证券股份有限公司杭州教工路证券营业部 | 1639.80 | 13.85 | | 买三 | 机构专用 | 1329.87 | 375.51 ...

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

证券代码：002082 证券简称：万邦德 公告编号：2025-036 针对公司股票异常波动情况，按照相关规定的要求，公司对有关事项进行了 核查，现就核实情况说明如下： 1、前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3、公司目前经营情况正常，不存在内外部经营环境发生重大变化的情形； 4、公司、控股股东和实际控制人不存在关于公司应披露而未披露的重大事项 或处于筹划阶段的重大事项； 一、股票交易异常波动的情况介绍 万邦德医药控股集团股份有限公司 万邦德医药控股集团股份有限公司(以下简称"公司"）股票连续 2 个交易日内 （2025 年 5 月 30 日，2025 年 6 月 3 日）收盘价格涨幅偏离值累计达到 21.67%， 根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动。 关于股票交易异常波动的公告 二、公司关注并核实的情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 五、备查文件 1、关于股票交易异常波动的问询函及回复。 特此公告。 万邦德医药控股 ...

Market Overview - The three major A-share indices rebounded collectively, with the Shanghai Composite Index rising by 0.48%, the Shenzhen Component Index by 0.35%, and the ChiNext Index by 0.73% [1] - The total market turnover reached 763.9 billion yuan, a decrease of 7.7 billion yuan compared to the same period of the previous trading day [1] - Over 3,400 stocks in the market experienced gains [1] Sector Performance - The gold sector led the market, with Western Gold hitting the daily limit [1][9] - The innovative drug sector remained active, with stocks like Wanbangde and Qianhong Pharmaceutical also hitting the daily limit [1] - The new consumption concept saw renewed activity, with stocks like Ruoyuchen and Wancheng Group hitting their historical highs [1][12] Sports Sector Impact - The Jiangsu City Football League ("Su Chao") attracted significant attention, with 15,669 fans attending a match despite rain [3] - The popularity of "Su Chao" translated into the capital market, with Jinling Sports hitting a 20% limit up and 11 stocks in the Jiangsu sector reaching their daily limits [4][6] Gold Market Insights - Gold prices rebounded, with COMEX gold futures surpassing $3,400 per ounce [11] - The gold sector in both A-shares and Hong Kong stocks showed strong performance, with several companies like China Silver Group and Zijin Mining also experiencing gains [9][11] New Consumption Trends - The new consumption sector saw significant growth, with stocks like Ruoyuchen and Wancheng Group achieving historical highs [12] - Recent data indicated that several new consumption stocks have seen their prices more than double, with Ruoyuchen and Wancheng Group increasing over four times [18]

| 002100 | 天康生 | 3.02 | 6.15 | 1769.28 | 3.26 | | --- | --- | --- | --- | --- | --- | | | 物 | | | | | | 688298 | 东方生 | 5.85 | 3.76 | 1719.04 | 9.15 | | | 物 | | | | | | 000661 | 长春高 新 | -0.01 | 0.93 | 1656.66 | 4.26 | | 300009 | 安科生 物 | -1.00 | 2.05 | 1238.08 | 5.52 | | 600332 | 白云山 | 0.45 | 0.36 | 1038.50 | 7.56 | | 60021 1 | 西藏药 业 | 2.26 | 2.12 | 796.73 | 3.16 | | 000813 | 德展健 | 0.61 | 3.09 | 680.49 | 3.06 | | | 康 | | | | | | 603718 | 海利生 物 | 0.56 | 1.62 | 462.24 | 6.15 | | 603858 | 步长制 | 1.09 | 0.64 | 456 ...

一、行情回顾 市场全天震荡调整，创业板指领跌。创新药概念逆势大涨，睿智医药、海南海药、哈三联等多股涨停。猪肉、鸡肉股拉升，巨星农牧、湘佳股份封板。银行 股继续走强，杭州银行、成都银行创历史新高。下跌方面，高位股集体大跌，王子新材等多股跌停。个股跌多涨少，沪深京三市超4100股飘绿，今日成交 1.16万亿。 根据渤海证券统计，本周多款创新药获批上市，包括恒瑞医药的瑞康曲妥珠单抗、磷罗拉匹坦帕洛诺司琼、苹果酸法米替尼，复星医药的枸橼酸伏维西利、 芦沃美替尼，百济神州的泽尼达妥单抗，泽璟制药的盐酸吉卡昔替尼等，同时美国关税政策边际变化带动 CXO 板块快速反弹。 2025年美国临床肿瘤学会（ASCO）即将于当地时间5月30日至6月3日在美国芝加哥召开。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华森制药 | 4天4板 | 20.63 | +10.03% | 09:32:48 | 4.42% | 63.72亿 | 公司旗下5个产品完 美拉唑碳酸氢钠 ...